CPT1A and acute myeloid leukemia: Overall, CPT1A expression is abnormally high in AML, and targeted suppression of CPT1A has potent anti-leukemic effects, suggesting that CPT1A might be a therapeutic target for the treatment of AML (Mao et al., 2021).